Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jennifer A. Kowalski is active.

Publication


Featured researches published by Jennifer A. Kowalski.


Bioorganic & Medicinal Chemistry Letters | 2009

5-Aminomethylbenzimidazoles as potent ITK antagonists

Doris Riether; Renee M. Zindell; Jennifer A. Kowalski; Brian Nicholas Cook; Jörg Bentzien; Stephane De Lombaert; David S. Thomson; Stanley Kugler; Donna Skow; Leslie Martin; Ernest L. Raymond; Hnin Hnin Khine; Kathy O’Shea; Joseph R. Woska; Deborah D. Jeanfavre; Rosemarie Sellati; Kerry L. M. Ralph; Jennifer Ahlberg; Gabriel Labissiere; Mohammed A. Kashem; Steven S. Pullen; Hidenori Takahashi

Benzamide 1 demonstrated good potency as a selective ITK inhibitor, however the amide moiety was found to be hydrolytically labile in vivo, resulting in low oral exposure and the generation of mutagenic aromatic amine metabolites. Replacing the benzamide with a benzylamine linker not only addressed the toxicity issue, but also improved the cellular and functional potency as well as the drug-like properties. SAR studies around the benzylamines and the identification of 10n and 10o as excellent tools for proof-of-concept studies are described.


Bioorganic & Medicinal Chemistry Letters | 2010

Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method

Jennifer A. Kowalski; Alan David Swinamer; Ingo Muegge; Anne Bettina Eldrup; Alison Kukulka; Charles L. Cywin; Stephane De Lombaert

A 270-membered library of trisubstituted ureas was synthesized and evaluated for inhibition of soluble epoxide hydrolase. Library design and reagent selection was guided by the use of a pharmacophore model and synthesis of the array was enabled with a general solid-phase method. This array approach facilitated multi-dimensional SAR around this series and identified functionality responsible for binding affinity, as well as opportunities for modulating the overall in vitro profiles of this class of soluble epoxide hydrolase inhibitors.


Bioorganic & Medicinal Chemistry Letters | 2016

N-Arylsulfonyl-α-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity

Asitha Abeywardane; Gary O. Caviness; Younggi Choi; Derek Cogan; Amy Gao; Daniel R. Goldberg; Alexander Heim-Riether; Debra Jeanfavre; Elliott S. Klein; Jennifer A. Kowalski; Wang Mao; Craig Andrew Miller; Neil Moss; Philip Dean Ramsden; Ernest L. Raymond; Donna Skow; Lana Smith-Keenan; Roger J. Snow; Frank Wu; Jiang-Ping Wu; Yang Yu

Compound 1 ((4-amino-3,5-dichlorophenyl)-1-(4-methylpiperidin-1-yl)-4-(2-nitroimidazol-1-yl)-1-oxobutane-2-sulfonamido) was discovered to be a 690nM antagonist of human CCR10 Ca2+ flux. Optimization delivered (2R)-4-(2-cyanopyrrol-1-yl)-S-(1H-indol-4-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutane-2-sulfonamido (eut-22) that is 300 fold more potent a CCR10 antagonist than 1 and eliminates potential toxicity, mutagenicity, and drug-drug-interaction liabilities often associated with nitroaryls and anilines. eut-22 is highly selective over other GPCRs, including a number of other chemokine receptors. Finally, eut-22 is efficacious in the murine DNFB model of contact hypersensitivity. The efficacy of this compound provides further evidence for the role of CCR10 in dermatological inflammatory conditions.


Molecular Cell | 2007

Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase

Stefan Kubicek; Roderick J. O'Sullivan; E. Michael August; Eugene R. Hickey; Qiang Zhang; Miguel Teodoro; Stephen Rea; Karl Mechtler; Jennifer A. Kowalski; Carol Ann Homon; Terence A. Kelly; Thomas Jenuwein


Bioorganic & Medicinal Chemistry Letters | 2007

Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.

Roger J. Snow; Asitha Abeywardane; Scot Campbell; John Lord; Mohammed A. Kashem; Hnin Hnin Khine; Josephine King; Jennifer A. Kowalski; Steven S. Pullen; Teresa Roma; Gregory P. Roth; Christopher Ronald Sarko; Noel S. Wilson; Michael P. Winters; John P. Wolak; Charles L. Cywin


Archive | 2006

Soluble epoxide hydrolase inhibitors and methods of using same

Stephane De Lombaert; Anne Bettina Eldrup; Jennifer A. Kowalski; Ingo Andreas Mugge; Fariba Soleymanzadeh; Alan David Swinamer; Steven John Taylor


Archive | 2010

Cxcr3 receptor antagonists

Jennifer A. Kowalski; Daniel Richard Marshall; Anthony S. Prokopowicz; Sabine Schlyer; Robert Sibley; Ronald John Sorcek; Di Wu; Frank Wu; Erick Richard Roush Young


Archive | 2007

Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors

Anne Bettina Eldrup; Neil A. Farrow; Jennifer A. Kowalski; Stephane Delombaert; Ingo Andreas Mugge; Fariba Soleymanzadeh; Alan David Swinamer; Steven John Taylor


Archive | 2010

Derivatives of 6,7-dihydro-5h-imidazo[1,2-.alpha.]imidazole-3-carboxylic acid amides

Antonio Jose del Moral Barbosa; Joerg Martin Bentzien; Steven Richard Brunette; Zhidong Chen; Derek Cogan; Donghong A. Gao; Alexander Heim-Riether; Joshua Courtney Horan; Jennifer A. Kowalski; Michael David Lawlor; Rene Marc Lemieux; Weimin Liu; Bryan Mckibben; Craig Andrew Miller; Neil Moss; Matt Aaron Tschantz; Zhaoming Xiong; Hui Yu; Yang Yu


Archive | 2011

N-cyclyl-3 - (cyclylcarbonylaminomethyl) benzamide derivatives as rho kinase inhibitors

Brian Nicholas Cook; Jennifer A. Kowalski; Xiang Li; Daniel Richard Marshall; Sabine Schlyer; Robert Sibley; Lana Smith-Keenan; Fariba Soleymanzadeh; Ronald John Sorcek; Erick Richard Roush Young; Yunlong Zhang

Collaboration


Dive into the Jennifer A. Kowalski's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge